Mode
Text Size
Log in / Sign up
Phase 4 N=62 Randomized Triple-blind Treatment

Citicoline for Alcohol Dependence

Alcohol Dependence

Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Heavy Drinking Days Per Week — 0.23; 0.33 days/week

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Placebo (Drug); Citicoline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Oct 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Heavy Drinking Days Per Week
0.23; 0.33

Summary

The purpose of this study is to determine if citicoline, as an add-on therapy, will help reduce alcohol use in outpatients with alcohol dependence.

Eligibility Criteria

Inclusion Criteria

  • Men and women age 18-75 years old with diagnosis of alcohol dependence
  • Average alcohol use of at least 28 drinks per week and at least 7 heavy drinking days (defined as 4 or more drinks/day for women, 5 or more drinks/day for men) in the past 28 days
  • No alcohol use within 72 hours of randomization (maximum abstinence 7 days)
  • CIWA-Ar (withdrawal scale) score less than or equal to 8 at randomization (consistent with minimal or no withdrawal symptoms and medication probably not needed)

Exclusion Criteria

  • Vulnerable populations including individuals with intellectual disability or dementia, prison or jail inmates, pregnant or nursing women, or women of childbearing age who will not use acceptable forms of birth control
  • History of arrhythmias
  • Myocardial infarction or coronary artery bypass graft surgery in the past 6 months
  • Active angina or blood pressure >170/105
  • High risk for suicide (defined as suicide attempt in past 6 months, or current suicidal ideation with plan and intent)
  • High risk of violence toward others (defined as assault in past 6 months, or violent thoughts with evidence of plan and intent)
  • Intensive outpatient treatment for substance abuse (AA, NA meetings or weekly therapy/counseling for substance use for at least 28 days prior to randomization will be allowed)
  • Dependence (not just abuse) on substances other than alcohol or nicotine
  • History of delirium tremens or other sever alcohol withdrawal symptoms, history of cirrhosis or AST or ALT >3 times normal, or other unstable medical condition (e.g. uncontrolled diabetes)
  • History of bipolar disorder or schizophrenia
  • Current major depressive episode (past episodes and current milder depressive symptoms allowed) or other psychiatric disorder that should be a major focus of treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02074735). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search